Antibody Drug Conjugates Market Forecasts (2026-2030) by Cancer, Payload, Target, Product, User and Country/Region with Executive and Consultant Guides

1.1 Situation Analysis
1.2 Guide for Executives and Marketing Staff
1.3 Guide for Investment Analysts and Management Consultants

2.1 What are Antibody Drug Conjugates?
2.2 Immunotherapy - the looming cures
2.3 Market Definition
2.3.1 Market Size
2.3.2 Currency
2.3.3 Years
2.4 Methodology
2.4.1 Methodology
2.4.2 Sources
2.4.3 Authors
2.5 U.S. Medical Market and Pharmaceutical Spending - Perspective
2.5.1 Global Expenditures for Medicines

3.1 The Immune System
3.1.1 Innate immune system
3.1.1.1 Surface barriers
3.1.1.2 Inflammation
3.1.1.3 Complement system
3.1.1.4 Cellular barriers
3.1.1.5 Natural killer cells
3.1.2 Adaptive immune system
3.1.2.1 Lymphocytes
3.1.2.2 Killer T cells
3.1.2.3 Helper T cells
3.1.2.4 Gamma delta T cells
3.1.2.5 B lymphocytes and antibodies
3.1.3 Tumor immunology - the immune surveillance system
3.2 ADC Technology
3.2.1.1 Outlook for Antibody Drug Conjugates
3.2.1.2 Selected Companies with Antibody Drug Conjugates in their Pipeline

4.1 Market Players - Roles & Impacts
4.1.1 Drug manufacturers - Larger/pharmaceutical
4.1.2 Drug manufacturers - Generic
4.1.3 Contract Research and Manufacturing
4.1.4 In Vitro Diagnostics Industry
4.1.5 Drug Marketing Companies
4.1.6 Biotechnology Companies
4.1.7 Regulatory Bodies

5.1 Factors Driving Growth
5.1.1 Outcome potential
5.1.2 Fast tracking
5.1.3 Funding
5.1.4 Technology Environment
5.1.5 Target Solutions
5.2 Factors Limiting Growth
5.2.1 Cost of Treatment
5.2.2 Clinical Trials Role
5.2.3 Combinations
5.2.4 Protocols
5.3 Therapeutic Technology Development
5.3.1 Combinations - Issues and Complexity
5.3.2 Preference for a drug
5.3.3 Problems of Immunity Engineering
5.3.4 The Role of Cost
5.3.5 The Disruption Dynamic
5.4 Global Sales of Antibody-drug Conjugates (ADCs) in 2024
5.4.1 Enhertu Sales in 2024/2023
5.4.2 Kadcyla Sales in 2024/2023
5.4.3 Padcev Sales in 2024/2023
5.4.4 Adcetris Sales in 2024/2023
5.4.5 Trodelvy Sales in 2024/2023
5.4.6 Polivy Sales in 2024/2023
5.4.7 The Next Five Years

6.1 Recent Developments - Importance and How to Use This Section
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 Merck secures $700 million to develop ADC therapy
6.3 Enhertu tops Roche’s Kadcyla
6.4 Innovent signs $11.4 billion cancer therapy deal with Takeda
6.5 Tubulis raises $358 million to develop targeted cancer treatments
6.6 Roche closes $80M deal for lung cancer ADC
6.7 Trodelvy and Keytruda combo succeeds in Phase 3
6.8 GSK acquires rights for prostate cancer ADC
6.9 Samsung Bioepis and Phrontline partner for ADC development
6.10 Phrontline Biopharma raises $60M for bispecific and dual-payload ADCs
6.11 Kelun has phase 3 win for ADC-Keytruda combo
6.12 Datopotamab deruxtecan Biologics License Application accepted
6.13 FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
6.14 AstraZeneca to build $1.5-bln ADC plant
6.15 Samsung Biologics expands into ADC manufacturing and services
6.16 Ipsen and Foreseen Biotechnology announce licensing agreement for ADC
6.17 PDCs vs. ADCs: A New Frontier
6.18 MilliporeSigma launches single-use reactor for ADC manufacturing
6.19 Ono to generate novel ADC candidates
6.20 Gilead and Tubulis to develop ADC candidate for solid tumor

7.1 ADC Therapeutics
7.2 AbbVie
7.3 Abzena
7.4 Adcendo
7.5 Adcentrx Therapeutics
7.6 Adcytherix
7.7 Alentis Therapeutics
7.8 Alphamab Oncology
7.9 Alteogen
7.10 Ambrx
7.11 Amgen
7.12 Antengene
7.13 Astellas Pharma
7.14 Axcynsis Therapeutics
7.15 Axplora
7.16 BeiGene
7.17 BeOne Medicines
7.18 BioAtla
7.19 Bio-Thera Solutions
7.20 Biotheus
7.21 BiVictriX Therapeutics
7.22 BioNTech
7.23 Bicycle Therapeutics
7.24 Bolt Biotherapeutics
7.25 Bright Peak Therapeutics
7.26 Bristol Myers Squibb (BMS)
7.27 Byondis
7.28 Callio Therapeutics
7.29 Catalent Biologics
7.30 CSPC Pharmaceutical Group
7.31 CytomX Therapeutics
7.32 Daiichi Sankyo
7.33 Debiopharm
7.34 Duality Biologics
7.35 Eisai
7.36 Eli Lilly
7.37 Exelixis
7.38 Fosun Pharma
7.39 Genentech (Roche)
7.40 Genmab
7.41 GenScript Biotech
7.42 Gilead Sciences
7.43 GlaxoSmithKline (GSK)
7.44 Hansoh Pharma
7.45 Hengrui Pharma
7.46 Heidelberg Pharma
7.47 Iksuda Therapeutics
7.48 ImmunoGen
7.49 Innate Pharma
7.50 Innovent Biologics
7.51 iProgen Biotech
7.52 Janssen Biotech (Johnson & Johnson)
7.53 Kelun-Biotech
7.54 KLUS Pharma
7.55 LegoChem Biosciences (LegoChemBio)
7.56 Lepu Biopharma
7.57 Lonza Pharma & Biotech / Synaffix
7.58 MacroGenics
7.59 MBrace Therapeutics
7.60 MediLink Therapeutics
7.61 Merck & Co. (MSD)
7.62 Merck KGaA (EMD Serono)
7.63 Mersana Therapeutics
7.64 Molecular Templates
7.65 NBE Therapeutics (a subsidiary of Boehringer Ingelheim)
7.66 Novartis
7.67 OBI Pharma
7.68 OmniAb
7.69 Oncomatryx
7.70 OnCusp Therapeutics
7.71 Orum Therapeutics
7.72 Oqory
7.73 Oxford BioTherapeutics
7.74 Pacylex Pharmaceuticals
7.75 Pfizer
7.76 Phrontline Biopharma
7.77 ProfoundBio
7.78 Promega
7.79 Pyxis Oncology
7.80 Radiance Biopharma
7.81 Rakuten Aspyrian (Aspyrian Therapeutics)
7.82 RemeGen
7.83 Roche
7.84 Rongchang Pharmaceuticals (RCBio)
7.85 Sanofi
7.86 Seagen
7.87 Solve Therapeutics (Solve Tx)
7.88 Sorrento Therapeutics
7.89 Starpharma
7.90 Sutro Biopharma
7.91 Synaffix (a Lonza Company)
7.92 SystImmune
7.93 Takeda Pharmaceutical
7.94 Tesaro / GSK Oncology
7.95 Tubulis
7.96 UCB
7.97 VelosBio
7.98 WuXi XDC
7.99 Xencor
7.100 Zai Lab

8.1 Global Market Overview by Country
8.1.1 Table - Global Market by Country
8.1.2 Chart - Global Market by Country
8.2 Global Market by Cancer - Overview
8.2.1 Table - Global Market by Cancer
8.2.2 Chart - Global Market by Cancer - Base/Final Year Comparison
8.2.3 Chart - Global Market by Cancer - Base Year
8.2.4 Chart - Global Market by Cancer - End Year
8.2.5 Chart - Global Market by Cancer - Share by Year
8.2.6 Chart - Global Market by Cancer - Segments Growth
8.3 Global Market by Payload - Overview
8.3.1 Table - Global Market by Payload
8.3.2 Chart - Global Market by Payload - Base/Final Year Comparison
8.3.3 Chart - Global Market by Payload - Base Year
8.3.4 Chart - Global Market by Payload - End Year
8.3.5 Chart - Global Market by Payload - Share by Year
8.3.6 Chart - Global Market by Payload - Segments Growth
8.4 Global Market by Target - Overview
8.4.1 Table - Global Market by Target
8.4.2 Chart - Global Market by Target - Base/Final Year Comparison
8.4.3 Chart - Global Market by Target - Base Year
8.4.4 Chart - Global Market by Target - End Year
8.4.5 Chart - Global Market by Target - Share by Year
8.4.6 Chart - Global Market by Target - Segments Growth
8.5 Global Market by Product - Overview
8.5.1 Table - Global Market by Product
8.5.2 Chart - Global Market by Product - Base/Final Year Comparison
8.5.3 Chart - Global Market by Product - Base Year
8.5.4 Chart - Global Market by Product - End Year
8.5.5 Chart - Global Market by Product - Share by Year
8.5.6 Chart - Global Market by Product - Segments Growth
8.6 Global Market by User - Overview
8.6.1 Table - Global Market by User
8.6.2 Chart - Global Market by User - Base/Final Year Comparison
8.6.3 Chart - Global Market by User - Base Year
8.6.4 Chart - Global Market by User - End Year
8.6.5 Chart - Global Market by User - Share by Year
8.6.6 Chart - Global Market by User - Segments Growth

9.1 Breast
9.1.1 Table Breast - by Country
9.1.2 Chart - Breast Growth
9.2 Blood/Lymph Cancer
9.2.1 Table Blood Cancer - by Country
9.2.2 Chart - Blood Cancer Growth
9.3 Lung Cancer
9.3.1 Table Lung Cancer - by Country
9.3.2 Chart - Lung Cancer Growth
9.4 Other Cancer
9.4.1 Table Other Cancer - by Country
9.4.2 Chart - Other Cancer Growth

10.1 Auristatin
10.1.1 Table Auristatin - by Country
10.1.2 Chart - Auristatin Growth
10.2 Maytansinoid
10.2.1 Table Maytansinoid - by Country
10.2.2 Chart - Maytansinoid Growth
10.3 Topoisomerase
10.3.1 Table Topoisomerase - by Country
10.3.2 Chart - Topoisomerase Growth
10.4 Other Payload
10.4.1 Table Other Payload - by Country
10.4.2 Chart - Other Payload Growth

11.1 HER2
11.1.1 Table HER2 - by Country
11.1.2 Chart - HER2 Growth
11.2 CD30
11.2.1 Table CD30 - by Country
11.2.2 Chart - CD30 Growth
11.3 TROP2
11.3.1 Table TROP2 - by Country
11.3.2 Chart - TROP2 Growth
11.4 CD79b
11.4.1 Table CD79b - by Country
11.4.2 Chart - CD79b Growth
11.5 Nectin 4
11.5.1 Table Nectin 4 - by Country
11.5.2 Chart - Nectin 4 Growth
11.6 Other Target
11.6.1 Table Other Target - by Country
11.6.2 Chart - Other Target Growth

12.1 Enhertu
12.1.1 Table Enhertu - by Country
12.1.2 Chart - Enhertu Growth
12.2 Kadcyla
12.2.1 Table Kadcyla - by Country
12.2.2 Chart - Kadcyla Growth
12.3 Padcev
12.3.1 Table Padcev - by Country
12.3.2 Chart - Padcev Growth
12.4 Adcetris
12.4.1 Table Adcetris - by Country
12.4.2 Chart - Adcetris Growth
12.5 Trodelvy
12.5.1 Table Trodelvy - by Country
12.5.2 Chart - Trodelvy Growth
12.6 Polivy
12.6.1 Table Polivy - by Country
12.6.2 Chart - Polivy Growth
12.7 Other Product
12.7.1 Table Other Product - by Country
12.7.2 Chart - Other Product Growth

13.1 Clinical
13.1.1 Table Clinical - by Country
13.1.2 Chart - Clinical Growth
13.2 Trial
13.2.1 Table Trial - by Country
13.2.2 Chart - Trial Growth
13.3 Research
13.3.1 Table Research - by Country
13.3.2 Chart - Research Growth
13.4 Other User
13.4.1 Table Other User - by Country
13.4.2 Chart - Other User Growth

14.1 FDA Cancer Drug Approvals by Year
14.2 Clinical Trials Started
14.3 Prevalence of Cancer Treatments

Table 1 List of Cancers by Mortality
Table 2 Overview of Innate and Adaptive Immunity
Table 3 Some Antibody Drug Conjugate Companies
Table 4 Market Players by Type
Table 5 Five Factors Driving Growth
Table 6 Four Factors Limiting Growth
Table 7 Global Market by Region
Table 8 Global Market by Cancer
Table 9 Global Market by Payload
Table 10 Global Market by Target
Table 11 Global Market by Product
Table 12 Global Market by User
Table 13 Breast by Country
Table 14 Blood Cancer by Country
Table 15 Lung Cancer by Country
Table 16 Other Cancer by Country
Table 17 Auristatin by Country
Table 18 Maytansinoid by Country
Table 19 Topoisomerase by Country
Table 20 Other Payload by Country
Table 21 HER2 by Country
Table 22 CD30 by Country
Table 23 TROP2 by Country
Table 24 CD79b by Country
Table 25 Nectin 4 by Country
Table 26 Other Target by Country
Table 27 Enhertu by Country
Table 28 Kadcyla by Country
Table 29 Padcev by Country
Table 30 Adcetris by Country
Table 31 Trodelvy by Country
Table 32 Polivy by Country
Table 33 Other Product by Country
Table 34 Clinical by Country
Table 35 Trial by Country
Table 36 Research by Country
Table 37 Other User by Country

Figure 1 Medicine Expenditures Perspective
Figure 2 Helper T Cell Roles
Figure 3 Antibody Diagram
Figure 4 Macrophages attack a Cancer Cell
Figure 5 Antibody Drug Conjugate Diagram
Figure 6 Growth rates of ADC Therapies
Figure 7 Global Market Pareto Chart
Figure 8 Global Market by Cancer - Base vs. Final
Figure 9 Global Market by Cancer Base Year
Figure 10 Global Market by Cancer End Year
Figure 11 Cancer Share by Year
Figure 12 Cancer Segments Growth
Figure 13 Global Market by Payload - Base vs. Final
Figure 14 Global Market by Payload Base Year
Figure 15 Global Market by Payload End Year
Figure 16 Payload Share by Year
Figure 17 Payload Segments Growth
Figure 18 Global Market by Target - Base vs. Final
Figure 19 Global Market by Target Base Year
Figure 20 Global Market by Target End Year
Figure 21 Target Share by Year
Figure 22 Target Segments Growth
Figure 23 Global Market by Product - Base vs. Final
Figure 24 Global Market by Product Base Year
Figure 25 Global Market by Product End Year
Figure 26 Product Share by Year
Figure 27 Product Segments Growth
Figure 28 Global Market by User - Base vs. Final
Figure 29 Global Market by User Base Year
Figure 30 Global Market by User End Year
Figure 31 User Share by Year
Figure 32 User Segments Growth
Figure 33 Breast Growth
Figure 34 Blood Cancer Growth
Figure 35 Lung Cancer Growth
Figure 36 Other Cancer Growth
Figure 37 Auristatin Growth
Figure 38 Maytansinoid Growth
Figure 39 Topoisomerase Growth
Figure 40 Other Payload Growth
Figure 41 HER2 Growth
Figure 42 CD30 Growth
Figure 43 TROP2 Growth
Figure 44 CD79b Growth
Figure 45 Nectin 4 Growth
Figure 46 Other Target Growth
Figure 47 Enhertu Growth
Figure 48 Kadcyla Growth
Figure 49 Padcev Growth
Figure 50 Adcetris Growth
Figure 51 Trodelvy Growth
Figure 52 Polivy Growth
Figure 53 Other Product Growth
Figure 54 Clinical Growth
Figure 55 Trial Growth
Figure 56 Research Growth
Figure 57 Other User Growth
Figure 58 FDA Cancer Drug Approvals by Year
Figure 59 Clinical Trials for Immunotherapy by Year
Figure 60 Pie Chart of Prevalence of Cancer Treatments